[Pubmed] Identification of key genes as potential diagnostic and therapeutic targets for comorbidity of myasthenia gravi
Posté : 22 févr. 2024 12:00
Front Neurol. 2024 Feb 7;14:1334131. doi: 10.3389/fneur.2023.1334131. eCollection 2023.
ABSTRACT
INTRODUCTION: Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder. Coronavirus disease 2019 (COVID-19) has a significant impact on the health and quality of life of MG patients and may even trigger the onset of MG in some cases. With the worldwide development of the COVID-19 vaccination, several new-onset MG cases and exacerbations following the COVID-19 vaccines have been acknowledged. The potential link between myasthenia gravis (MG) and COVID-19 has prompted the need for further investigation into the underlying molecular mechanism.
METHODS AND RESULTS: The differential expression analysis identified six differentially expressed genes (DEGs) shared by myasthenia gravis (MG) and COVID-19, namely SAMD9, PLEK, GZMB, JUNB, NR4A1, and NR1D1. The relationship between the six common genes and immune cells was investigated in the COVID-19 dataset. The predictive value of the shared genes was assessed and a nomogram was constructed using machine learning algorithms. The regulatory miRNAs, transcription factors and small molecular drugs were predicted, and the molecular docking was carried out by AutoDock.
DISCUSSION: We have identified six common DEGs of MG and COVID-19 and explored their immunological effects and regulatory mechanisms. The result may provide new insights for further mechanism research.
PMID:38384322 | PMC:PMC10879883 | DOI:10.3389/fneur.2023.1334131
Source: https://pubmed.ncbi.nlm.nih.gov/3838432 ... t9+e462414